Axsome Therapeutics
AXSM
34 hedge funds and large institutions have $43.7M invested in Axsome Therapeutics in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
100% more funds holding
Funds holding: 17 → 34 (+17)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
3% less capital invested
Capital invested by funds: $45.2M → $43.7M (-$1.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.55M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.05M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$512K |
| 4 |
Mariner
Overland Park,
Kansas
|
+$382K |
| 5 |
Morgan Stanley
New York
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.14M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$938K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$114K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$101K |
| 5 |
SCM
Segantii Capital Management
Hong Kong
|
-$68K |
AXSM Hedge Fund Activity: Q2 2016 in Review
34 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2016, worth a combined $43.7M — down 3.3% from $45.2M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AXSM positions and 3 closed out — a net gain of 17 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.55M. The largest seller was Fidelity Investments, cutting an estimated $1.14M.
- 34 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2016, up from 17 in Q1 2016.
- Funds reported $43.7M of Axsome Therapeutics stock for Q2 2016, down 3.3% quarter-over-quarter.
- 20 funds opened new Axsome Therapeutics positions in Q2 2016 and 3 closed out, a net change of +17 holders.
- The largest Axsome Therapeutics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $2.55M added.
- The largest Axsome Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2016.